CAE Inc. (TSE:CAE – Get Free Report) (NYSE:CAE)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$32.82 and last traded at C$32.73, with a volume of 411264 shares changing hands. The stock had previously closed at C$32.45.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. Scotiabank lifted their price target on CAE from C$30.00 to C$32.50 in a report on Thursday, November 14th. Canaccord Genuity Group boosted their price target on CAE from C$28.00 to C$30.00 in a research report on Thursday, November 14th. TD Securities raised their price target on CAE from C$33.00 to C$34.00 and gave the company a “buy” rating in a report on Thursday, November 14th. CIBC upped their price objective on shares of CAE from C$30.00 to C$33.00 in a report on Thursday, November 14th. Finally, Royal Bank of Canada raised their target price on shares of CAE from C$27.00 to C$34.00 in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, CAE currently has a consensus rating of “Hold” and a consensus price target of C$32.35.
View Our Latest Research Report on CAE
CAE Stock Up 0.8 %
About CAE
CAE Inc, together with its subsidiaries, provides simulation training and critical operations support solutions in Canada, the United States, the United Kingdom, Europe, Asia, Oceania and Africa, and Rest of Americas. It operates through three segments: Civil Aviation, Defense and Security, and Healthcare.
See Also
- Five stocks we like better than CAE
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Insider Buying Explained: What Investors Need to Know
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for CAE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAE and related companies with MarketBeat.com's FREE daily email newsletter.